Kornimate/medical-research-clean huggingface dataset:
icare for cancer patients

Conditions: Myelodysplastic Syndromes; Acute Myeloid Leukemia; Acute Myelogenous Leukemia; Acute Lymphoid Leukemia; Leukemia, Acute Lymphoblastic; Multiple Myeloma; Myelofibrosis

Summary: the purpose of this study is to use genomic information from individual patients to create simulation avatars that will be used to predict novel drug combinations with therapeutic potential.

as part of normal clinical care, subjects will undergo peripheral blood draws and biopsies for disease assessment of their cancer. in cases of hematological malignancies, bone marrow aspiration \& biopsy are routinely performed. as part of this project, the following will be done to the samples collected and with clinical outcomes data: * donate peripheral blood specimens whenever blood is already being drawn for clinical purposes. * donate bone marrow aspiration samples whenever a bone marrow aspiration procedure is already being done for clinical purposes. * donate saliva whenever blood draw is already being done for clinical purposes. * allow the investigators to perform gene mutation profiling. * allow the investigators to study gene mutation results. * allow the investigators to perform pharmacogenetic profiling. * allow the investigators to study pharmacogenetic profiles. * allow the investigators to examine chromosome copy number variations. * allow the investigators to examine genomic methylation. * allow the investigators to quantify metabolomics/cytokines.

Eligibility criteria:
inclusion criteria: * individuals known or suspected of having a blood cancer or hematologic disorder * individuals with presence of extramedullary disease * capable of providing informed consent. exclusion criteria: * does not have a blood cancer or a hematologic disorder
pleurostrain: interest of strain ultrasound in the diagnosis of pneumothorax

Conditions: Pneumothorax

Summary: the objective of this study is to investigate whether the use of strain ultrasound can improve the lung ultrasound accuracy for the diagnosis of pneumothorax, particularly for inexperienced physicians.

prospective multi-centre diagnostic study based on the post-interpretation of recorded ultrasound loops as part of standard patient management.

Eligibility criteria:
inclusion criteria: * age over 17 years old * management in an investigative centre * presenting a suspicion of pneumothorax * having had a pulmonary ultrasound scan * having had a ct scan within 2 hours after or before the pulmonary ultrasound exclusion criteria: * pregnant or breastfeeding women * persons not covered by a social security scheme * persons deprived of their liberty * the patient is participating in another study * the patient is in an exclusion period determined by a previous study * the patient is under the protection of justice, guardianship or curatorship * patient refuses to participate * it is impossible to give informed information about * the patient does not read french fluently * patient with any known pulmonary pathology pre-existing prior to the hospitalization episode * patient with a lung condition other than pneumothorax on a scanner

Keywords: pont-of-care ultrasound
error augmentation training post stroke

Conditions: Stroke

Summary: post-stroke individuals continue to suffer from significant motor impairments years after the stroke. motor recovery is usually limited to the first 6 month after the stroke, in which the majority of improvements occur at the first three months. error augmentation (ea) training using a robotic apparatus was suggested to enhance motor recovery by exploiting the adaptation mechanisms within the intact cerebellum in individuals who sustained cortical stroke. the aim of this study is to investigate whether error augmentation training for the upper extremity may enhance motor recovery in individuals that sustained cortical stroke. fifty post-stroke individuals will be randomaly assigned into either ea training (study group- sg) or robotic training in null field environment (control group- cg). both groups will carry out the same treatment protocol on the robotic device in addition to the standard rehabilitation protocol of the rehabilitation center. treatment protocol will be consisted of about six training sessions on the robotic device, taken twice or three times a week for two to three weeks. each training session will be composed of 20-30 minutes upper extremity training with or without ea force field. motor performance will be evaluated before and after the treatment protocol by the fugl-meyer assessment scale.

post-stroke individuals continue to suffer from significant motor impairments years after the stroke. motor recovery is usually limited to the first 6 month after the stroke, in which the majority of improvements occur at the first three months. error augmentation (ea) training using a robotic apparatus was suggested to enhance motor recovery by exploiting the adaptation mechanisms within the intact cerebellum in individuals who sustained cortical stroke. the aim of this study is to investigate whether error augmentation training for the upper extremity may enhance motor recovery in individuals that sustained cortical stroke. fifty post-stroke individuals will be randomaly assigned into either ea training (study group- sg) or robotic training in null field environment (control group- cg). both groups will carry out the same treatment protocol on the robotic device in addition to the standard rehabilitation protocol of the rehabilitation center. treatment protocol will be consisted of about six training sessions on the robotic device, taken twice or three times a week for two to three weeks. each training session will be composed of 20-30 minutes upper extremity training with or without ea force field. motor performance will be evaluated before and after the treatment protocol by the fugl-meyer assessment scale.

Eligibility criteria:
inclusion criteria: * cortical stroke, unilateral hemiparesis exclusion criteria: * other neurological disorders (alzheimer's disease, pd), complete plegia,unilateral neglect,sensory aphasia, mini mental state examination\<20

Keywords: stroke error augmentation rehabilitation cerebellum motor learning adaptation
ipv and lung compliance in invasively ventilated children

Conditions: Pediatric Acute Respiratory Distress Syndrome (PARDS); Pediatric Respiratory Diseases; Lung Compliance

Summary: the goal of this observational study is to determine if intrapulmonary percussive ventilation (ipv) improves lung compliance in children receiving conventional invasive mechanical ventilation. the main questions it aims to answer are: 1. does ipv improve lung compliance 15 minutes after and 3 hours after receiving one treatment in a heterogeneous group of pediatric patients? 2. does ipv improve lung compliance in patients with pediatric acute respiratory distress syndrome (pards), and what is the degree of change compared to those without pards? 3. what is the effect of ipv on lung compliance according to pards severity (mild-moderate disease vs. severe disease). 4. what is the incidence of adverse effects of ipv? participants will receive ipv because their medical team feels it will help their lung recovery and has already determined them to be safe candidates to receive this therapy, which is a standard airway clearance modality already routinely used in our picu. nothing additional will happen to participants as a result of this study. enrolling in this study simply gives the study team permission to collect specific health information that identifies your child for research purposes, which may include results from medical tests found in their medical record and information from your child's bedside monitor and ventilator. this information will be collected before and after the ipv treatments to evaluate their response to the therapy.


Eligibility criteria:
inclusion criteria: * ≤18 years old on conventional intermittent mandatory ventilation in the picu that the physician deems is a candidate for ipv exclusion criteria: * the inability to accurately obtain ventilator measurements

Keywords: lung compliance pediatric pediatric acute respiratory distress syndrome (pards) intrapulmonary percussive ventilation (ipv)
single dose crossover study of patient preference for unscented nasonex® nasal spray versus scented flonase® nasal spray (study p04207)

Conditions: Allergic Rhinitis

Summary: this was a one-day single dose trial conducted to compare patient's preference for nasonex® (mometasone) versus flonase® nasal spray. each patient was randomized to take one dose (2 sprays in each nostril) of nasonex or flonase. thirty minutes later, each patient was to take one dose of the opposite medication. questionnaires were given to each patient after each drug dose to evaluate patient product preference.


Eligibility criteria:
inclusion criteria: * subject must have been 18-65 years of age, of either sex and any race. * subject must have had symptomatic allergic rhinitis with a total nasal symptom (congestion, rhinorrhea, sneezing, itching) severity score of \ 2; congestion must have been \<2. * subject must have been free of any clinically significant disease (other than allergic rhinitis) that would interfere with study evaluations. * subject must have understood and been able to adhere to the dosing and visit schedule. exclusion criteria: * subject had used any investigational product within 30 days prior to enrollment. * subject was in a situation or condition that, in the opinion of the investigator, may have interfered with optimal participation in the study. * subject was participating in any other clinical study(ies). * subject was using any nasal lavage fluid or spray. * subject was using any perfume during the study day. * subject was using any oral rinse during the study day. * subject had used topical or oral nasal decongestants in the past 1 week. * subject had used a nasal corticosteroid in the previous 2 weeks. * subject had anosmia or ageusia (absence of the sense of smell or taste). * subject had been using medications which are associated with anosmia or ageusia in the 2 weeks prior to testing. * subject had a respiratory infection in the 2 weeks prior to testing.
study on quality of life in advanced cancer patients with opioid-induced constipation treated with naloxegol

Conditions: Opioid Use; Constipation Drug Induced; Cancer

Summary: opioid-induced constipation (oic) is often associated with a compromised quality of life of patients in palliative care (pc) setting. among the peripherally-acting mu-opioid receptor antagonists, naloxegol is the most effective to treat oic and to improve oic-related aspects of quality of life in patients with non-cancer pain. this observational study aims to assess the impact of a 4-weeks naloxegol therapy on the quality of life in advanced cancer patients with oic assisted by a home pc program. the study is enrolling cancer patients with oic (defined according to rome iv criteria) not relieved by first-line laxatives, starting the therapy with 25 mg/day of naloxegol. the main parameters evaluated at the beginning of the therapy (t0) and after 28 days (t28) are: patient assessment of constipation quality-of-life (pac-qol, 4 subscales: physical discomfort, psychosocial discomfort, worries and concerns, satisfaction), evaluation of objective (number of weekly evacuations) and subjective constipation (bowel function index, bfi, normal score\<30), pain assessment by nrs.


Eligibility criteria:
inclusion criteria: * cancer patients with advanced disease; * age higher than 18 years; * mentally competent; * naloxegol therapy for no more than 1 week according to clinical practice; * sign of a written informed consent. exclusion criteria: * patient with pain not controlled by opioids; * therapy with other pamoras; * intestinal obstruction; * risk of intestinal perforation. * severe renal failure.

Keywords: opioid induced constipation cancer patients palliative care quality of life pac-qol naloxegol
exogenous ketones in type 2 diabetes

Conditions: Ketosis; Type 2 Diabetes

Summary: exogenous ketone supplements are proposed to have glucose-lowering potential, provide an alternative fuel for the brain and to enhance cognitive function. no studies have tested whether exogenous ketones can lower blood glucose in people with type 2 diabetes. in addition, the impact of exogenous ketones on brain blood flow, cognitive function or brain-derived neurotrophic factor in humans is unknown. the purpose of this study is to determine if acutely ingesting exogenous ketones, in the form of a ketone monoester drink, can lower glucose and improve measures of brain/cognitive function in humans with type 2 diabetes. participants will consume a ketone monoester drink or placebo with blood samples, brain blood flow, and cognitive function assessed over 180 minutes. the researchers will also test how the ketone monoester drink impacts appetite and measures of inflammation.


Eligibility criteria:
inclusion criteria: * physician-diagnosed type 2 diabetes of ≥1 year * current hemoglobin a1c (hba1c) of 6.5-8.0% * treatment with lifestyle or stable (≥3 months) oral glucose-lowering medications * blood pressure of \<160/99 mm hg assessed according to guidelines * non-smoking * no prior history of cardiovascular disease or stroke * not on hormone replacement therapy, corticosteroids, or anti-inflammatory medications * 20-75 years old exclusion criteria: * being a competitive endurance athlete * taking exogenous insulin or sodium glucose transporter 2 (sglt2) inhibitors * following a ketogenic diet, low-calorie diet, periodic fasting regimen, or consume ketogenic supplements * being unable to travel to and from the university * being unable to follow the controlled diet instructions * being pregnant or planning to become pregnant during the study (if female) * disorders of fat metabolism, chronic pancreatitis, had gastric bypass surgery and/or gallbladder disease * being unable to read or communicate in english
a study to evaluate the safety, tolerability and efficacy of ain457 in patients with relapsing-remitting multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the study will assess the long-term safety and tolerability of ain457 in patients with relapsing-remitting multiple sclerosis (rrms). in addition the long-term pattern of maintenance of efficacy and health related quality of life will be explored.


Eligibility criteria:
inclusion criteria: 1. was exposed to ain457 or placebo in study cain457b2201 and completed the cain457b2201 study, up to at and including visit 10 (week 24). exclusion criteria: 1. have been treated with: * immunosuppressive medications such as azathioprine or methotrexate within 1 month prior to enrollment, if lymphocyte count normal. * immunoglobulins and/or monoclonal antibodies (with the exception of ain457) within 2 month prior to enrollment, or if the immunosuppressive effects are likely to persist at enrollment (such as presence of b cell depletion after rituximab treatment). 2. have received total lymphoid irradiation, bone marrow transplantation, alemtuzumab, cladribine, cyclophosphamide, mitoxantrone or other immunosuppressive treatments with long-lasting (over 6 months) or permanent effects. 3. have received any live or live attenuated vaccines (including live vaccines for varicella-zoster virus or measles) within 2 months prior to enrollment. 4. a diagnosis of chronic disease of the immune system other than ms, or of an immunodeficiency syndrome. 5. current severe depression. 6. pregnant or nursing (lactating) women. 7. malignancy diagnosed since enrollment in the core study (except for successfully-treated basal or squamous cell carcinoma of skin). 8. a new diagnosis of diabetes 9. positive testing for tuberculosis (quantiferon or chest x-ray). 10. subjects with clinically significant cardiac abnormalities 11. unable or unwilling to undergo multiple venipunctures 12. unable to undergo mri scans due to newly acquired claustrophobia or metallic implants incompatible with mri. other protocol-defined inclusion/exclusion criteria may apply

Keywords: multiple sclerosis, demyelinating autoimmune diseases, interleukin-17, monoclonal human antibody
cricothyroidotomy training for physicians outcomes study

Conditions: Airway Obstruction

Summary: this study will assess whether the type of simulation model used in cricothyroidotomy training has an effect on the subsequent confidence and competence in the procedure.

this is a pilot study - prospective randomised controlled trial involving: 1. assessment of ability to complete a surgical cricothyroidotomy 2. completion of questionnaire prior to training and prior to assessment prior to beginning training, questionnaires will be completed by all participants asking their level of previous training. current confidence level for completion of cricothyroidotomy will be marked on a visual analogue scale (vas). training will then be completed with each group using the appropriate manikin type - porcine or synthetic. this will consist of didactic information on the procedure delivered via recorded information to standardise this initial training, and then proceeding to supervised practice of the procedure for two occasions. this will be completed by the same trainer, with the same information given to both groups. questions to clarify how to perform the procedure will be permitted. the second questionnaire will be given to the trainees on completion of training to mark on a visual analogue scale their confidence level at this point. assessment will then be completed later the day comprising of assessment of completion of surgical cricothyroidotomy using a porcine manikin with skin overlying. this will be different to the porcine manikin used for training. the assessment will time the trainees from start to completion of airway insertion, as well as a checklist of activities to be achieved. the porcine manikins will then be dissected to identify if correct location for insertion was achieved and complications. the same amount of time will be given between groups training and assessment.

Eligibility criteria:
inclusion criteria: * medically trained healthcare professionals working in anaesthetics, emergency medicine or general surgery as these doctors may be expected to complete a surgical cricothyroidotomy despite infrequently performing the procedure. * the healthcare professionals can be from foundation year 1 to before certificates of completion of training (cct). those who are out of training and are not yet at consultant level are also eligible. * able to provide informed consent. exclusion criteria: • healthcare professionals who already complete surgical airways on a regular basis (e.g. ear nose throat or maxillofacial trainees) as these doctors may already be competent prior to training.
a safety and efficacy study of botox® (botulinum toxin type a) in patients with urinary incontinence due to neurogenic detrusor overactivity or overactive bladder in india

Conditions: Urinary Incontinence; Overactive Bladder

Summary: this is a post-marketing surveillance study in india to evaluate safety and efficacy of botox® (botulinum toxin type a) in the treatment of patients with urinary incontinence due to neurogenic detrusor overactivity or overactive bladder.


Eligibility criteria:
inclusion criteria: * patients with urinary incontinence due to ndo or oab treated with botox® as per local standard of care in clinical practice. exclusion criteria: * none
study to predict the need for humidification use and comparison of the effect of thermosmart™ and no humidification on adherence

Conditions: Sleep Apnea, Obstructive

Summary: despite the effectiveness of continuous positive airway pressure (cpap) in abolishing upper airway obstruction, acceptance of and adherence with therapy has been sub-optimal. one of the only technological advancements shown to increase adherence is heated humidification, now considered part of conventional cpap therapy in some countries. thermosmart™ is a unique technology developed by fisher \& paykel healthcare which utilises a heated breathing tube to deliver optimal humidity in all environments. thermosmart has been shown to be superior to conventional humidification in reducing side effects, condensation and titrated pressure as well as increasing total sleep time. however, improved humidity delivery has not lead to significantly increased adherence in unselected obstructive sleep apnea (osa) patients. a total of 80 patients diagnosed with osa but naive to cpap use will be randomized into a single blind, randomized, parallel-arm trial to determine whether the the use of heated humidification will impact therapy adherence.


Eligibility criteria:
inclusion criteria: * diagnosed with osa * naïve to cpap therapy, i.e have not been prescribed, or used cpap in the last 5 years * prescribed a nasal mask (as patients will be prescribed their mask following recruitment into the study, any participants who are prescribed a full face mask will be withdrawn) exclusion criteria: * severe heart disease * co-existing lung disease * co-existing sleep disorders * pregnant

Keywords: obstructive sleep apnea humidification continuous positive airway pressure icon thermosmart
a trial to compare the pharmacodynamic and pharmacokinetic properties of biochaperone® combo with humalog® mix25 and with simultaneous injections of humalog® and lantus® in subjects with type 2 diabetes

Conditions: Type 2 Diabetes Mellitus

Summary: this is a single centre, randomised, double-blind, double-dummy, 3-treatment, 3-period cross-over, euglycaemic clamp study in subjects with type 2 diabetes on stable insulin treatment. each subject will be randomly allocated to a treatment sequence and will be administered single subcutaneous doses of 0.8 u/kg biochaperone® combo, 0.8 u/kg humalog® mix25 or simultaneous subcutaneous injections of 0.2 u/kg humalog® and 0.6 u/kg lantus® during three separate dosing visits.


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus (as diagnosed clinically) for ≥ 12 months * hba1c levels ≤ 9.0% * total insulin dose of \< 1.2 u/kg/day * body mass index between 20.0 and 35.0 kg/m2 (both inclusive) * body weight ≤ 125.0 kg * fasting serum c-peptide ≤ 1 nmol/l * treated with a stable insulin regimen for ≥ 3 months prior to screening exclusion criteria: * type 1 diabetes mellitus * known or suspected allergy to the trial products or related products * previous participation in this trial. participation is defined as randomised * participation in any clinical trial within 3 months prior to this trial * clinically significant abnormal haematology, biochemistry, lipids, or urinalysis screening tests, as judged by the investigator considering the underlying disease * supine blood pressure at screening outside the range of 90-160 mmhg for systolic or 50-95 mmhg for diastolic and/or resting supine heart rate outside the range 50 -90 beats per minute. this exclusion criterion also pertains to subjects being on antihypertensives * use of glp-1 receptor agonists or oral antidiabetic drugs (oads) other than stable intake of metformin within 4 weeks prior to screening * women of child bearing potential, not willing to use contraceptive methods